the first is comparing weekly tirzepatide (5, 10, or 15 mg) against weekly dulaglutide 0.75 mg in Japanese people taking no other glucose-lowering medications during the trial, and the primary endpoint is a change in HbA1c, and the second is a safety study that will monitor adverse events in Japanese people given tirzepatide (5, 10, or 15 mg) in addition to non-incretin-based antidiabetes medications over 52 weeks of treatment
Drinking excessive water without adequate electrolyte intake can worsen hyponatremia, the very condition we discussed in the SIADH section
Why You Might Feel Lightheaded on Semaglutide There are several physiological reasons why someone might experience dizziness or fainting while using a GLP-1 medication
GLP1-RAs are hypothesized to be a promising therapy for slowing the progression of diabetic CKD [18]
Patients with active inflammation, frequent flares, or recent hospitalisations are generally not suitable candidates
Many people include electrolyte supplements as part of their daily routine while taking GLP-1 medications because eating less can reduce both fluid and mineral intake